{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-026765","form_type":"8-K","ticker":"TOVX","cik":"0000894158","company_name":"Theriva Biologics, Inc.","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.972500+00:00","generated_at":"2026-05-15T14:34:45.081754+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Theriva Biologics FY2025 cash $13.1M; licensing deal, EMA guidance on VCN-01 Phase 3","bullets":["G&A expense rose 109% to $15.4M on $9.0M contingent consideration from VCN-01 trial success.","R&D expense fell 28% to $8.6M as VIRAGE Phase 2b completed; lower trial costs offset by patent spending.","Cash $13.1M at Dec 31, 2025; $15.2M at Feb 26, 2026 providing runway into Q1 2027.","Licensed SYN-020 to Rasayana for up to $38M milestones plus royalties; received $300K upfront.","EMA agreed on Phase 3 trial design for VCN-01 in PDAC; End-of-Phase 2 FDA meeting planned 1H 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-026765","json":"https://secwatch.observer/filing/0001104659-26-026765.json","markdown":"https://secwatch.observer/filing/0001104659-26-026765.md","text":"https://secwatch.observer/filing/0001104659-26-026765.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/894158/000110465926026765/0001104659-26-026765-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/894158/000110465926026765/tm268491d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:34:45.081754+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}